GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Identifying novel resistance mechanisms in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)

$187,642
John Sfakianos · Icahn School Of Medicine At Mount Sinai · R21 · FY2024 · CA

Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition

$187,514
Maria De Los Angeles Lopez-Olivo · University Of Tx Md Anderson Can Ctr · K08 · FY2022 · CA

Signaling Mechanisms in Genome Maintenance (Equipment Supplement 2023)

$187,421
Marcus Smolka · Cornell University · R35 · FY2023 · GM

Development Therapeutics Branch Clinical Trials

$187,121
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Developing GRB2-PROTACs for Treatment of Lung Cancer

$187,087
Haitao Mark Ji · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2024 · CA

Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy and Immunotherapy

$186,978
Bo Lu · Thomas Jefferson University · R01 · FY2021 · CA

Prediction and Treatment for Cancer Immunotherapy Induced Myocarditis

$186,875
Hua Pan · University Of South Florida · R21 · FY2021 · HL

Dissecting the interactions between TCR signaling strength and inhibitory pathways

$186,840
Lin Shen · University Of Chicago · K08 · FY2025 · AI

Dissecting the interactions between TCR signaling strength and inhibitory pathways

$186,840
Lin Shen · University Of Chicago · K08 · FY2024 · AI

Endocrine tissue molecular pathways dysregulated by immune checkpoint inhibitors causing ICI-triggered adverse events

$186,532
Yaron Tomer · Albert Einstein College Of Medicine · R21 · FY2024 · CA

Deregulation of the Ubiquitin/26S Proteasome Pathway in AT cells: Role of ISG15

$186,375
Shyamal D Desai · Lsu Health Sciences Center · R21 · FY2009 · NS

Remotely controlled listerial bactodrones for cancer immunotherapy

$186,018
Mark Gomelsky · University Of Wyoming · R21 · FY2021 · CA

CORRELATIVE SCIENCE CORE

$185,997
Jon C Aster · Brigham And Women'S Hospital · P50 · FY2018 · CA

Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming

$185,977
Samuel G Katz · Yale University · R21 · FY2024 · CA

Regulation of BRCA1 Function by Protein Phosphatase 1

$185,920
Lih-Ching Hsu · Magee-Women'S Res Inst And Foundation · R01 · FY2007 · CA

Analysis of lung cancer stem cell radioresistance

$185,845
Vera Levina · University Of Pittsburgh At Pittsburgh · R21 · FY2013 · CA

Redefining hemophagocytic lymphohistiocytosis in hematologic malignancies

$185,831
Michael Jordan · Cincinnati Childrens Hosp Med Ctr · R21 · FY2021 · CA

Discovery of PD-1/PDL-1 inhibitors from marine microbial natural products

$185,808
William Fenical · University Of California, San Diego · R01 · FY2023 · CA

Discovery of PD-1/PDL-1 inhibitors from marine microbial natural products

$185,807
William Fenical · University Of California, San Diego · R01 · FY2022 · CA

Project 2: Chemotherapy-induced Immunomodulation in Colon Cancer

$185,625
Pran K Datta · University Of Alabama At Birmingham · U54 · FY2021 · CA

Prostate cancer-associated SPOP mutations modulate innate immune response and immune checkpoint therapy

$185,552
Timothy C Thompson · University Of Tx Md Anderson Can Ctr · R21 · FY2022 · CA

PVSRIPO in melanoma

$185,397
Georgia Beasley · Duke University · K08 · FY2024 · CA

Molecular Targeting of the Survivin Pathway in Cancer

$185,238
Univ Of Massachusetts Med Sch Worcester · R01 · FY2002 · CA

Metabolic basis of ARID1A-mutated ovarian cancer

$184,954
Rugang Zhang · Wistar Institute · R01 · FY2022 · CA

In vivo CRISPR-screening of novel cancer cell-intrinsic targets that sensitize to local ionizing radiation, and possible combination with systemic checkpoint blockade.

$184,822
Ralph R Weichselbaum · University Of Chicago · R21 · FY2023 · CA